MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial For Its Pediatric Asthma Product Candidate
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that in a pharmacokinetic clinical trial Unit Dose Budesonide (UDB) demonstrated lower systemic drug exposure when compared to the currently marketed conventional nebulized budesonide. UDB is MAP Pharmaceuticals’ proprietary nebulized formulation of budesonide, currently in Phase 3 clinical development, for the potential treatment of pediatric asthma. UDB is designed […]
Dal asthma test bests spirometry
Click Here For Asthma Breakthrough!
A new device cobbled together out of a stereo speaker, some transducers and a breathing tube by scientists at Dalhousie University in Halifax could revolutionize the way we diagnose asthma.
Called a forced oscillation spirometer, the machine measures how resistant or “twitchy” an asthma patient’s airways are, explains Dr Paul Hern¡andez, a […]
